Please login to the form below

Not currently logged in
Email:
Password:

Santhera

This page shows the latest Santhera news and features for those working in and with pharma, biotech and healthcare.

Encouraging data for GenSight’s blinding retinal disease gene therapy

Encouraging data for GenSight’s blinding retinal disease gene therapy

If approved, the gene therapy would compete with Santhera's Raxone, which became the first approved treatment for LHON in Europe in 2015.

Latest news

More from news
Approximately 5 fully matching, plus 10 partially matching documents found.

Latest appointments

  • Shires's Jeffrey Jonas to lead Sage Shires's Jeffrey Jonas to lead Sage

    The other key appointments are AstraZeneca's Stephen Kanes as chief medical officer and Santhera's Kimi Iguchi as chief financial officer. ... Iguchi joins from her role as chief operating officer, North America, for Santhera.

  • Santhera CEO Klaus Schollmeier joins SuppreMol Santhera CEO Klaus Schollmeier joins SuppreMol

    He has experience at ING BHF-Bank, BASF, Knoll and Abbott. Former CEO of Santhera Pharmaceuticals Klaus Schollmeier has joined Germany-based biopharma SuppreMol as CEO. ... Dr Schollmeier (pictured right) had served as CEO of Santhera since its formation

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Healthcircle

    Novo Nordisk. Otsuka. Pfizer. Roche. Santen. Santhera. Schwabe. Pelviva. Unicough.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics